Terms: = Uterine cancer AND PRKACA, MGC48865, 5566, ENSG00000072062, P17612, PKACA, MGC102831
5 results:
1. KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma.
Saglam O; Tang Z; Tang G; Medeiros LJ; Toruner GA
PLoS One; 2020; 15(9):e0238477. PubMed ID: 32877461
[TBL] [Abstract] [Full Text] [Related]
2. Non-invasive stereotactic ablative boost in patients with locally advanced cervical cancer.
Dalwadi S; Echeverria A; Jhaveri P; Bui T; Waheed N; Tran D; Bonnen M; Ludwig M
Int J Gynecol Cancer; 2020 Nov; 30(11):1684-1688. PubMed ID: 32636273
[TBL] [Abstract] [Full Text] [Related]
3. HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and \textit{EPB41L3} methylation classifier.
Brentnall AR; Vasiljevic N; Scibior-Bentkowska D; Cadman L; Austin J; Cuzick J; Lorincz AT
Cancer Biomark; 2015; 15(5):669-75. PubMed ID: 26406956
[TBL] [Abstract] [Full Text] [Related]
4. Can Genomic Amplification of Human Telomerase Gene and C-MYC in Liquid-Based Cytological Specimens Be Used as a Method for Opportunistic Cervical cancer Screening?
Gao K; Eurasian M; Zhang J; Wei Y; Zheng Q; Ye H; Li L
Gynecol Obstet Invest; 2015; 80(3):153-63. PubMed ID: 25832290
[TBL] [Abstract] [Full Text] [Related]
5. Peritoneal cytology: a risk factor of recurrence for non-endometrioid endometrial cancer.
Han KH; Park NH; Kim HS; Chung HH; Kim JW; Song YS
Gynecol Oncol; 2014 Aug; 134(2):293-6. PubMed ID: 24854062
[TBL] [Abstract] [Full Text] [Related]
